FDA approved Dr. Reddy’s ANDA for Lansoprazole delayed-release capsules

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Dr. Reddy’s Laboratories announced that it will be launching Lansoprazole delayed-release capsules (15 mg and 30 mg), a bioequivalent generic version of Prevacid®* Delayed-Release Capsules, in the US market. The Food & Drug Administration (FDA) approved Dr. Reddy’s ANDA for Lansoprazole delayed-release capsules on October 15, 2010. Launch preparations are complete and shipments will commence shortly. Dr. Reddy’s Lansoprazole delayed-release capsules are available in bottles of 30 & 90 counts in 15mg and 90 and 500 counts in 30 mg.

GSK Licences COPD Drug from Empirico for $85 Million Upfront

KLN Named Exclusive Distributor for Siemens Healthineers Point-of-Care Testing Solutions in…

Thermo Fisher to Acquire Clario Holdings for $8.9bn

Simtra BioPharma Expands High-Quality Sterile Injectables

Applications of the TXA2 Rat ELISA Kit in Cardiovascular Disease Research

Future-proof vial filling – How flexibility Along the Line Defines Success

How Smart Digital Strategies are Leading the Way in Pharmaceutical Manufacturing

Rethinking Real-World Data Partnerships: How to Fill Gaps Without Starting Over

Energy efficiency in pure steam generation: How small adjustments can lead…

Pharmacovigilance Systems Gaining Higher Ground with AI

KLN Named Exclusive Distributor for Siemens Healthineers Point-of-Care Testing Solutions in…

API China Strengthens its Role as Asia’s Pharma Powerhouse

swop 2025: Celebrating Ten Years of Industry Growth

swop 2025: A Decade of Global Packaging Innovation

Thermo Fisher Showcases AI, Accelerator at CPHI Frankfurt

FDA approved Dr. Reddy’s ANDA for Lansoprazole delayed-release capsules

GSK Licences COPD Drug from Empirico for $85 Million Upfront

KLN Named Exclusive Distributor for Siemens Healthineers Point-of-Care Testing Solutions in Hong Kong

Thermo Fisher to Acquire Clario Holdings for $8.9bn

Simtra BioPharma Expands High-Quality Sterile Injectables

GSK Licences COPD Drug from Empirico...

KLN Named Exclusive Distributor for Siemens...

CDMO Market for AAV Therapies to...

Pharmaceutical CMO Market is Set for...

Global CDMO Market for Cell and...

CDMOs Must Reorganize to Maximize Revenue...

GSK Licences COPD Drug from Empirico for $85 Million Upfront

KLN Named Exclusive Distributor for Siemens Healthineers Point-of-Care Testing Solutions in Hong Kong

Thermo Fisher to Acquire Clario Holdings for $8.9bn

Simtra BioPharma Expands High-Quality Sterile Injectables

About us

latest updates

System

subscribe us

Resources

Subscribe

GSK Licences COPD Drug from Empirico for $85 Million Upfront

KLN Named Exclusive Distributor for Siemens Healthineers Point-of-Care Testing Solutions in...